Novartis AG (NYSE:NVS) – Investment analysts at Leerink Swann cut their Q3 2017 earnings per share estimates for Novartis AG in a research note issued on Thursday. Leerink Swann analyst S. Fernandez now expects that the company will earn $1.20 per share for the quarter, down from their prior estimate of $1.21. Leerink Swann has a “Market Perform” rating and a $83.00 price objective on the stock. Leerink Swann also issued estimates for Novartis AG’s Q4 2017 earnings at $1.17 EPS, FY2017 earnings at $4.68 EPS, FY2018 earnings at $5.17 EPS and FY2019 earnings at $5.49 EPS.

Novartis AG (NYSE:NVS) last announced its earnings results on Tuesday, April 25th. The company reported $1.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.10 by $0.03. Novartis AG had a return on equity of 15.46% and a net margin of 13.10%. The business had revenue of $11.54 billion for the quarter, compared to analysts’ expectations of $11.59 billion. During the same period last year, the firm posted $1.17 earnings per share. The business’s revenue for the quarter was down .5% on a year-over-year basis. COPYRIGHT VIOLATION WARNING: “Q3 2017 EPS Estimates for Novartis AG Lowered by Analyst (NVS)” was posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/06/23/q3-2017-eps-estimates-for-novartis-ag-lowered-by-analyst-nvs.html.

Earnings History and Estimates for Novartis AG (NYSE:NVS)

Several other analysts also recently weighed in on the company. Barclays PLC upgraded Novartis AG from an “underweight” rating to an “equal weight” rating in a research note on Thursday. J P Morgan Chase & Co restated a “neutral” rating on shares of Novartis AG in a research note on Thursday. TheStreet upgraded Novartis AG from a “c+” rating to a “b” rating in a research note on Friday, June 2nd. Morgan Stanley restated a “sell” rating on shares of Novartis AG in a research note on Tuesday, June 6th. Finally, Zacks Investment Research upgraded Novartis AG from a “strong sell” rating to a “hold” rating in a research note on Monday, May 1st. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and five have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $83.10.

Novartis AG (NYSE:NVS) opened at 86.34 on Friday. The company has a market cap of $204.25 billion, a P/E ratio of 32.46 and a beta of 0.76. The stock has a 50 day moving average price of $80.41 and a 200 day moving average price of $75.45. Novartis AG has a 1-year low of $66.93 and a 1-year high of $86.90.

Several institutional investors have recently made changes to their positions in the stock. Howe & Rusling Inc. boosted its position in shares of Novartis AG by 192.2% in the first quarter. Howe & Rusling Inc. now owns 1,341 shares of the company’s stock worth $100,000 after buying an additional 882 shares during the last quarter. TCI Wealth Advisors Inc. boosted its position in shares of Novartis AG by 20.0% in the first quarter. TCI Wealth Advisors Inc. now owns 1,381 shares of the company’s stock worth $103,000 after buying an additional 230 shares during the last quarter. Archford Capital Strategies LLC boosted its position in shares of Novartis AG by 72.3% in the first quarter. Archford Capital Strategies LLC now owns 1,480 shares of the company’s stock worth $110,000 after buying an additional 621 shares during the last quarter. Kernodle & Katon Asset Management Group LLC boosted its position in shares of Novartis AG by 3.4% in the first quarter. Kernodle & Katon Asset Management Group LLC now owns 1,488 shares of the company’s stock worth $111,000 after buying an additional 49 shares during the last quarter. Finally, North Star Investment Management Corp. boosted its position in shares of Novartis AG by 50.3% in the first quarter. North Star Investment Management Corp. now owns 1,526 shares of the company’s stock worth $113,000 after buying an additional 511 shares during the last quarter. 11.37% of the stock is owned by institutional investors and hedge funds.

About Novartis AG

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.